COMMUNIQUÉS West-GlobeNewswire

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
25/03/2024
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and [...]
LifeMD to Participate in the 23rd Annual Needham Virtual Healthcare Conference
25/03/2024
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 23 rd Annual Needham Virtual [...]
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
25/03/2024
-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin [...]
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
25/03/2024
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON [...]
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
25/03/2024
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data [...]
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
25/03/2024
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces today it [...]
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
25/03/2024
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
25/03/2024
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi syndrome is the most common genetic cause of life- [...]
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
25/03/2024
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
25/03/2024
PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary [...]
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
25/03/2024
Major achievements in 2023 lay the foundation for key upcoming milestones SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company [...]
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
25/03/2024
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint [...]
One World Products, Inc. Secures Exclusive Rights With Procepack for State-of-the-Art PreRoll-Er Equipment in Colombia
25/03/2024
LAS VEGAS, NV, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Products, Inc. ("OWP") (OTCQB: OWPC), a trailblazer in hemp and cannabis production, proudly announces an exclusive agreement with [...]
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
25/03/2024
Currently Enrolling Phase 2 Study of BJT-778 in HDV; Interim Data Expected second half of 2024 SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical [...]
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
25/03/2024
MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases [...]
Olink reports fourth quarter and full year 2023 financial results
25/03/2024
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth [...]
Olink publishes 2023 annual report
25/03/2024
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink. [...]
Novo Nordisk A/S - share repurchase programme
25/03/2024
Bagsværd, Denmark, 25 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25/03/2024
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 [...]

Pages